Immunology and Inflammation Therapeutics Sector Outlook — September 2026
This report maps Immunology and Inflammation Therapeutics companies by business model, benchmarks forward revenue valuations, and reviews precedent transactions. It is for investors, corporate development teams and boards weighing where premium multiples are earned and what supports them.
For information only. Not an appraisal or a fairness opinion.
What moved since: Immunology and Inflammation Therapeutics M&A update, 14–28 September 2026
Key figures
- Sector median valuation
- 7.9x
- EV / Revenue (CY2026E)
- Premium tier valuation
- 42.2x
- top of range, two names
- Development-stage share
- 81%
- of approved company set
- Reference transaction value
- $2.9B
- Sanofi S.A./Provention Bio, Inc.
Read the report
1 / 20 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › IMMUNOLOGY AND INFLAMMATION THERAPEUTICS
Executive summary
The Immunology and Inflammation Therapeutics sector spans clinical-stage developers and adjacent commercial models, with EV / Revenue (CY2026E) ranging from 4.0x to 42.2x across the rated set. Clinical-stage developers make up 81% of the approved companies; faster growth does not correspond with a higher valuation in the six-name split. Precedent transactions, including the $2.9B Sanofi S.A./Provention Bio, Inc. deal, show strategic fit across several deal structures. Revenue durability, not forecast speed, appears to be what the market prices at the premium end.
Key findings
- Premium tier trades at 42.2x versus 4.0x at the discount end.
- Clinical-stage developers make up 81% of the approved company set.
- Faster-growing names carry lower forward revenue valuations in this split.
- Precedent deals span whole-company, pipeline and single-product structures.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › IMMUNOLOGY AND INFLAMMATION THERAPEUTICS
The cover page introduces the Immunology and Inflammation Therapeutics sector outlook dated September 28, 2026.
This report examines the Immunology and Inflammation Therapeutics sector as of September 28, 2026, using EV / Revenue (CY2026E) as the primary valuation lens. We'll walk through where forward revenue valuations sit and which operating choices can strengthen market standing.
Everything on this page
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › IMMUNOLOGY AND INFLAMMATION THERAPEUTICS Immunology and Inflammation: Premiums Need Proof The report shows where forward revenue valuations sit and which operating choices can strengthen market standing. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2026E) Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
The contents page lists the five report sections plus the appendix, starting with the bottom line.
We built this report so the first section carries the full argument, letting a reader who stops there still leave with the complete story. The five sections that follow walk through the landscape, valuation, precedent deals and strategic implications in turn.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Forward Valuations Separate Sharply Across Business Models 02 The Landscape Clinical-Stage Exposure Dominates, but Adjacent Models Bring Different Economics 03 Valuation & Situations The Premium End Demands Evidence Beyond a Forecast Ramp 04 Precedent Transactions Precedent Transactions Reward Strategic Fit Across Several Deal Structures 05 Strategic Implications Operating Proof Is the Practical Route to a More Defensible Position 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Immunology and Inflammation Therapeutics Spans Clinical-Stage Developers and Adjacent Commercial Models
This slide summarizes the sector's core findings on valuation, growth, business mix, and precedent deals.
We see the premium end of the sector trading at 42.2x versus 4.0x at the discount end, so durable revenue evidence is what defends that range. Clinical-stage developers make up 81% of the approved set, with adjacent commercial models at 19%, and the four developers carrying an estimate sit at 7.7x. On the six names split by growth, three sit above 23% and three below, and the faster-growing group carries the lower valuation — so ramp quality matters more than ramp speed. The precedent record includes the Sanofi S.A./Provention Bio, Inc. transaction at $2.9B and 4.9x, showing the scale available when an asset fits a larger platform. Together these findings frame this report's argument: premiums need proof.
Everything on this page
01 · THE BOTTOM LINE Immunology and Inflammation Therapeutics Spans Clinical-Stage Developers and Adjacent Commercial Models The full story on one page · figures on EV / Revenue (CY2026E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2026E consensus (7 of 16 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 A Premium Needs Durable Revenue Evidence The premium end stands at 42.2x versus 4.0x at the discount end, based on two names at each end. With a forward revenue lens already crediting forecast growth, commercial durability and pipeline evidence become central to defending the higher range. 2 Faster Forecasts Do Not Automatically Bring Higher Valuations On the six names in the growth split, three sit above 23% and three below. The faster-growing group carries the lower forward revenue valuation, so the quality and durability of the ramp remain important. 3 Development Exposure Shapes Most of the Sector Clinical-stage immunology and inflammation developers represent 81% of the approved set, while adjacent models represent 19%. The four developers with an estimate sit at 7.7x, leaving pipeline evidence and funding discipline central to their positioning. 4 Strategic Fit Matters Across the Transaction Record Seven transactions show buyers engaging with whole companies, pipeline combinations and an individual product. Sanofi S.A. and Provention Bio, Inc. provide a $2.9B reference at 4.9x, illustrating the scale available when an asset fits a larger pharmaceutical platform. 7.9x Sector median EV/Revenue CY2026E consensus · EV/Revenue is the lens because only 4 of 16 names carry a meaningful forward EBITDA 42.2x Premium end EV/Revenue vs 4.0x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/Revenue — the spread the report explains 7 Transactions with disclosed terms 12 recorded in this tier · 3 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces the section on the sector's clinical-stage and adjacent business model mix.
The sector combines clinical-stage development risk with the different economics of commercial, manufacturing and franchise models. We now turn to how that mix breaks down across the approved company set.
Everything on this page
SECTION 02 02 THE LANDSCAPE Clinical-Stage Exposure Dominates, but Adjacent Models Bring Different Economics The sector combines development risk with commercial, manufacturing and franchise economics. 02 of 06 Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Most Sector Exposure Sits in Development-Stage Models with Different Paths to Value
This slide groups the approved companies by business segment and shows median EV / Revenue (CY2026E) per group.
Grouping the approved set by business segment shows where sector exposure concentrates and where the economics differ. Clinical-stage developers represent 81% of the set, with adjacent models at 19%, and the developers carrying an estimate sit at a 7.7x median. That concentration means most of the sector's value depends on pipeline outcomes rather than in-market commercial execution — so we watch clinical evidence closely.
Everything on this page
02 · MARKET MAP Most Sector Exposure Sits in Development-Stage Models with Different Paths to Value 16 approved companies grouped by business segment · median EV / Revenue (CY2026E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE IMMUNOLOGY AND INFLAMMATION DEVELOPERS 13 cos median 7.7x argenx SE (ARGX) Abivax S.A. (ABVX) Spyre Therapeutics (SYRE) Arcutis (ARQT) Vera Therapeutics (VERA) DBV Technologies (DBVT) Alumis (ALMS) ARS (SPRY) Palisade Bio (PALI) Coya Therapeutics (COYA) aTyr Pharma (ATYR) ImageneBio (IMA) Immunic (IMUX) These companies depend on clinical evidence, treatment sequencing and funding choices to convert pipeline promise into durable revenue. ADJACENT MODELS 3 cos median 7.9x AbbVie (ABBV) Kiniksa (KNSA) Alvotech (ALVO) Commercial franchises, specialty products and biosimilars bring access, exclusivity and manufacturing economics into the valuation debate.
- 0602 · LANDSCAPE
Development-Stage Companies Dominate the Set, While Adjacent Models Broaden the Economic Mix
This slide presents a segment-level view of the approved universe with EV / Revenue (CY2026E) medians on rated names.
Looking at the approved universe by segment confirms that development-stage companies dominate the count, with adjacent models broadening the economic mix. The 81%/19% split between clinical-stage and adjacent models repeats what we saw at the group level, and the 7.7x median for rated developers anchors the valuation conversation. For a reader tracking capital allocation, this is the frame to hold: most exposure is still tied to pipeline execution.
Everything on this page
02 · LANDSCAPE Development-Stage Companies Dominate the Set, While Adjacent Models Broaden the Economic Mix Segment view of the approved universe · EV / Revenue (CY2026E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage immunology and inflammation developers 13 81% 7.7x argenx SE (ARGX) · Abivax S.A. (ABVX) · +11 more Development exposure dominates the set. This group represents 81% of approved companies and the four developers with an estimate sit at 7.7x. Clinical evidence, chronic-dosing safety, indication breadth and capital needs frame how owners can strengthen their standing. Adjacent models 3 19% 7.9x AbbVie Inc. (ABBV) · Kiniksa Pharmaceuticals International, plc (KNSA) · +1 more Adjacent economics remain meaningful. These businesses represent 19% of approved companies. Their value cases extend beyond clinical readouts to franchise durability, formulary access, net-price resilience, manufacturing execution and biosimilar competition.
- 07SECTION 03
03
This divider introduces the section on public market valuation across the sector.
Forward revenue valuations already credit expected growth, which raises the bar for durable execution. We turn next to how that plays out across the rated names.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium End Demands Evidence Beyond a Forecast Ramp Forward revenue valuations already credit expected growth, raising the bar for durable execution. 03 of 06 Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Premium End Asks Owners to Prove That the Forecast Ramp Can Endure
This slide ranks all rated companies by EV / Revenue (CY2026E) against the sector median.
Across the rated companies, the sector median EV / Revenue (CY2026E) sits at 7.9x, with the premium tier reaching 42.2x and the discount tier at 4.0x. We use EV/Revenue as the lens here because only a minority of the sixteen names carry a meaningful forward EBITDA figure. That spread means owners at the premium end need to keep proving the forecast ramp can hold — so evidence, not just growth expectations, is what the market is pricing.
Everything on this page
03 · PUBLIC MARKET VALUATION The Premium End Asks Owners to Prove That the Forecast Ramp Can Endure EV / Revenue (CY2026E) · all 7 rated companies, sorted descending · sector median 7.9x · EV/Revenue is the lens because only 4 of 16 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2026E consensus (7 of 16 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2026E) basis. Panel commentary is a NeuraCap view. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 42.2x CORE · median 7.9x DISCOUNT · median 4.0x Sector median 7.9x WHAT SEPARATES THE TWO ENDS The premium end carries conviction. Its 42.2x midpoint stands well above the 4.0x midpoint at the discount end, based on two names at each end. Forecasts already get credit. CY2026E EV / Revenue looks through current scale to expected revenue, so a lasting premium calls for evidence that the ramp can survive access, safety and treatment-sequencing pressure. The discount end needs proof. Owners can strengthen the case through durable patient starts, formulary access, persistence and disciplined funding rather than relying on the forecast alone.
- 0903 · VALUATION DRIVERS
Faster Forecast Growth Sits with the Lower Valuation in the Six-Name Split
This slide splits the rated names with estimates into faster and slower revenue-growth cohorts and compares their median valuations.
Splitting the six names with growth estimates at their covered median puts three names above 23% growth and three below. The faster-growing cohort carries the lower forward revenue valuation in this split, an association rather than a causal read. For owners, that means a fast forecast alone does not buy a premium multiple — the market appears to be pricing durability alongside speed.
Everything on this page
03 · VALUATION DRIVERS Faster Forecast Growth Sits with the Lower Valuation in the Six-Name Split Median EV / Revenue (CY2026E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=3; slower n=3; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 23% · EBITDA-margin split at n/a The Growth Split Does Not Show a Premium for Speed Among the six names in the split, the three above 23% carry a 6.2x midpoint versus 7.9x for the three below. The observation suggests that forecast speed alone does not distinguish the higher-valued group. Durability Matters Once Forecast Growth Is Already Credited A forward revenue multiple incorporates the expected ramp. Owners therefore need operating evidence around access, persistence, chronic-dosing safety and remaining exclusivity to support confidence beyond the forecast. Commercial Quality Can Separate Similar Growth Stories Net product sales, patient starts, formulary position and induction-to-maintenance conversion help distinguish a durable launch from one exposed to rebate pressure or restrictive treatment sequencing.
- 1003 · SITUATION MAP
Higher Forward Revenue Valuations Sit with the Higher-Margin Pair
This slide maps rated names against the sector's EV / Revenue median and EBITDA-margin median to characterize situations.
Cutting the rated set on the 7.9x sector median and the 33% covered EBITDA-margin median shows higher forward revenue valuations sitting with the higher-margin pair. Some rated names without the margin measure are not mapped here. These are observations on where names sit, not recommendations — but the pattern is one boards should have on the table when weighing margin discipline against growth investment.
Everything on this page
03 · SITUATION MAP Higher Forward Revenue Valuations Sit with the Higher-Margin Pair Cut on EV / Revenue vs the sector median (7.9x) (rows) and EBITDA margin vs the covered median (33%) (columns) · 3 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Higher Valuation, Higher Margin Above-median multiple · above-median EBITDA margin 2 names AbbVie Inc. (ABBV) · argenx SE (ARGX) AbbVie Inc. [ABBV] and argenx SE [ARGX] are the two mapped names with both measures above the relevant middle of the range. Their position is associated with established commercial economics, although the map does not establish why the market values them there. Higher Valuation, Lower Margin Above-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Lower Valuation, Higher Margin Below-median multiple · above-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Lower Valuation, Lower Margin Below-median multiple · below-median EBITDA margin 2 names Alvotech (ALVO) · Arcutis Biotherapeutics, Inc. (ARQT) Alvotech [ALVO] and Arcutis Biotherapeutics, Inc. [ARQT] are the two mapped names with both measures below the relevant middle of the range. Their position points owners toward commercial ramp quality, cost structure and capital allocation as the operating questions to resolve.
- 1103 · THE AGENDA
The Next Planning Cycle Turns on Four Choices: Revenue Mix, Pricing, Retention and Capital Allocation
This slide frames four planning questions on revenue mix, pricing, retention and capital allocation.
We frame the next planning cycle around four choices: revenue mix, pricing, retention and capital allocation. These are the questions an owner or acquirer should resolve, grounded in the cohort patterns shown earlier. Resolving them well is what turns a forecast ramp into a defensible market position.
Everything on this page
03 · THE AGENDA The Next Planning Cycle Turns on Four Choices: Revenue Mix, Pricing, Retention and Capital Allocation NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Concentrate Capital on Differentiated Clinical Evidence Prioritise programmes with a credible mechanism of action, meaningful endpoints and a clear place in treatment sequencing. A broad pipeline matters less when funding is spread across assets without distinct clinical evidence. What changes the answer: The answer changes when new data materially alters clinical remission, safety or positioning against the standard of care. Build Access into the Launch Plan Align pricing, formulary strategy and patient support around the realised revenue curve. Approval opens the market, while covered lives, step edits and prior-authorisation performance shape commercial uptake. What changes the answer: The answer changes when formulary placement or net-price durability departs from the launch plan. Choose Breadth Only Where One Mechanism Travels Fund additional indications where clinical evidence, specialist call points and development economics reinforce one another. Expansion without those links can add capital needs faster than strategic value. What changes the answer: The answer changes when an indication offers credible clinical separation and efficient use of existing capabilities. Use Partnerships Where Ownership Is Not Essential Licensing, territory rights and structured funding can preserve focus while moving programmes forward. The choice depends on capital capacity, geographic reach and the value of retaining future economics. What changes the answer: The answer changes when internal funding capacity or the strategic value of full ownership shifts.
- 12SECTION 04
04
This divider introduces the section on precedent transactions.
The transaction record spans whole companies, pipeline combinations and an individual product. We look next at what strategic fit looked like in each case.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Reward Strategic Fit Across Several Deal Structures The transaction record spans whole companies, pipeline combinations and an individual product. 04 of 06 Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12
- 1304 · DEAL CASE STUDIES
Precedent Transactions Show Several Routes to Strategic Fit
This slide presents a subset of disclosed-terms transactions as case studies illustrating different deal structures.
Among the transactions with disclosed terms, several are told here as case studies spanning different structures, including the $2.9B Sanofi S.A./Provention Bio, Inc. deal at 4.9x. Multiples shown are LTM at announcement and are not directly comparable to the CY2026E public basis, so we draw no spread between the two. The pattern across cases is that strategic fit — not just scale — explains why a deal happened. For owners, that is the lens worth applying before assuming any one deal structure is the model to follow.
Everything on this page
04 · DEAL CASE STUDIES Precedent Transactions Show Several Routes to Strategic Fit 3 of 7 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 19 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 5 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2026E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Mar-2023 $2.9B Sanofi S.A. Sanofi S.A. paired its pharmaceutical platform with Provention Bio, Inc. EV / LTM revenue 4.9x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The pairing suggests a path to apply established development, market-access and commercial capabilities to the target. It also fits the broader buyer pattern of larger pharmaceutical companies adding focused immunology exposure. HOW THE TARGET WAS VALUED The disclosed value was $2.9B at 4.9x EV / Revenue. That provides a revenue-based benchmark for a whole-company transaction involving a focused target. Oct-2022 $659M PureTech Health plc PureTech Health plc combined with Nektar Therapeutics, Inc. in a transaction centred on pipeline… EV / LTM revenue 6.9x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests a platform logic in bringing immunology programmes and development resources together. The fit appears strategic rather than dependent on a mature earnings stream. HOW THE TARGET WAS VALUED The disclosed value was $659M at 6.9x EV / Revenue. The multiple offers a benchmark for pipeline-oriented strategic fit within the transaction record. Jan-2023 $470M Vallon Pharmaceuticals, Inc. Vallon Pharmaceuticals, Inc. and GRI Bio, Inc. combined development-stage resources. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The pairing suggests a way to align development assets with an existing public-company platform. Its logic rests on the potential fit between the companies rather than a mature commercial franchise. HOW THE TARGET WAS VALUED The disclosed value was $470M. It provides a transaction-size reference for a development-stage combination.
- 14SECTION 05
05
This divider introduces the section on strategic implications for owners, management and boards.
Revenue quality, access, treatment sequencing and capital allocation are the areas warranting board attention. We close the analytical sections here before turning to what this means in practice.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Operating Proof Is the Practical Route to a More Defensible Position Revenue quality, access, treatment sequencing and capital allocation warrant board attention. 05 of 06 Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14
- 1505 · STRATEGIC IMPLICATIONS
Strengthen the Evidence Behind the Ramp Before Adding Cost or Pipeline Breadth
This slide lays out the questions this data puts on the table for the next twelve months.
Strengthening the evidence behind the ramp is the practical route to a more defensible position, ahead of adding cost or pipeline breadth. We frame this as questions for owners, management teams and boards to resolve over the next twelve months. These are observations grounded in the analysis, not directives — but they set the agenda for where attention belongs.
Everything on this page
05 · STRATEGIC IMPLICATIONS Strengthen the Evidence Behind the Ramp Before Adding Cost or Pipeline Breadth NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Tie Investment to Durable Revenue Quality Focus capital on clinical differentiation, access and persistence. Those operating outcomes make the forward revenue case easier to defend through payer pressure and competitive readouts. FOR MANAGEMENT TEAMS Manage the Launch Through Net Product Sales Patient starts matter, but gross-to-net deductions, formulary placement and time on therapy determine how demand becomes durable revenue. Resource allocation can follow the points where that conversion is most constrained. FOR BOARDS Match Ownership to Strategic Advantage Build where the company has differentiated science or commercial reach. Consider partnerships where another owner brings stronger territory access, registrational capacity or specialist coverage.
- 16SECTION 06
06
06.
Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 16
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16
- 1706 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / Revenue (CY2026E), Grouped by Valuation Tier
This slide lists the rated public comparables on EV / Revenue (CY2026E), grouped by valuation tier, alongside the unrated names.
The rated companies sit here against the 7.9x sector median, with tiers marked to show where each name lands. Additional names in the set carry no eligible EV/Revenue multiple and are not rated on this basis. This is the full comparable set behind every valuation figure used earlier in the report — so any number here can be traced back to its source.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2026E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (7.9x); amber marks below · 7 rated companies; 9 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 7 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2026E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥10.2x · median 42.2x · 2 companies Vera Therapeutics, Inc. VERA Clinical-stage immunology and inflammation developers $1.8B 73.0x n/a n/a n/a Kiniksa Pharmaceuticals International, plc KNSA Specialty inflammation pharmaceuticals $11.3B 11.3x 23% n/a n/a CORE — 5.9x–10.2x · median 7.9x · 3 companies argenx SE ARGX Clinical-stage immunology and inflammation developers $56.7B 9.2x 24% 34% 57 AbbVie Inc. ABBV Large-cap immunology franchise owners $534B 7.9x 9% 48% 60 Arcutis Biotherapeutics, Inc. ARQT Clinical-stage immunology and inflammation developers $3.3B 6.2x 28% 23% 63 DISCOUNT — <5.9x · median 4.0x · 2 companies Alvotech ALVO Specialty and biosimilar immunology manufacturers $3.3B 5.6x 22% 33% 60 ARS Pharmaceuticals, Inc. SPRY Clinical-stage immunology and inflammation developers $306M 2.4x 47% n/a n/a
- 1806 · PRECEDENT TRANSACTIONS (1 OF 1)
All Precedent Transactions with Disclosed Terms, Newest First
This slide lists the transactions with disclosed terms in the precedent set, ordered from newest to oldest.
The transactions with disclosed terms appear here, with multiples calculated on LTM financials at announcement. These figures are not directly comparable to the CY2026E public valuation basis, so no spread is implied between the two. This is the complete disclosed-terms record behind the case studies shown earlier in the report.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 1) All Precedent Transactions with Disclosed Terms, Newest First 7 transactions with disclosed terms in this tier (12 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 19 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 5 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2026E public basis and no spread is claimed. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2023 Sanofi S.A. → Provention Bio, Inc. $2.9B 4.9x n/a The Sanofi S.A. and Provention Bio, Inc. transaction suggests that a larger pharmaceutical owner can place a focused target within an established development and commercial platform. Jan-2023 Vallon Pharmaceuticals, Inc. → GRI Bio, Inc. $470M n/a n/a The Vallon Pharmaceuticals, Inc. and GRI Bio, Inc. pairing suggests a route for concentrating pipeline resources and public-company infrastructure. Oct-2022 PureTech Health plc → Nektar Therapeutics, Inc. $659M 6.9x n/a The PureTech Health plc and Nektar Therapeutics, Inc. transaction suggests strategic interest in consolidating immunology development exposure within a broader platform. Dec-2021 Assertio → Otrexup (methotrexate) product n/a 2.9x n/a Assertio's transaction for the Otrexup (methotrexate) product shows how an individual therapy can move independently of a whole company. Mar-2021 Roivant Sciences Ltd. → Immunovant Inc. n/a 0.7x 8.8x The terminated Roivant Sciences Ltd. and Immunovant Inc. transaction is a reminder that strategic alignment and completion risk are separate considerations. Aug-2020 Johnson & Johnson → Momenta Pharmaceuticals, Inc. $6.6B 0.7x 8.8x Johnson & Johnson's completed transaction for Momenta Pharmaceuticals, Inc. shows a diversified pharmaceutical buyer engaging with a focused immunology company. Aug-2020 Nestle S.A. → Aimmune Therapeutics, Inc. n/a 2.5x n/a The Nestle S.A. and Aimmune Therapeutics, Inc. transaction suggests that strategic interest can extend beyond traditional pharmaceutical buyers.
- 1906 · METHODOLOGY
Sources, Assumptions and Data Quality
This slide explains the report's sources, valuation assumptions, and how data-quality exclusions were handled.
This page sets out how the figures in this analysis were sourced, which basis was used for each valuation, and what was excluded and why. Every figure links back to the record it came from, so a client can trace any number to its origin. We include this detail so the analysis stands on a verifiable foundation.
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice 19 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2026E consensus (7 of 16 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2026E is the lead convention: it is the sector-appropriate prior for Immunology and Inflammation Therapeutics and it clears the coverage gate with 13 of 16 companies (81%). EV / EBITDA, P / E are carried as a cross-check. A revenue lens is used rather than a profit multiple because the cohort's median forward revenue growth is 27%, and a set priced on growth is read on revenue. DATA QUALITY & EXCLUSIONS 66 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 340 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (339) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 20
The Observed Premium Sits with Confidence in Revenue Durability, Not Forecast Speed Alone.
The closing page restates that the observed premium reflects confidence in revenue durability rather than forecast speed alone.
The observed premium in this sector sits with confidence in revenue durability, not forecast speed alone. Companion tables alongside this report carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.
Everything on this page
The Observed Premium Sits with Confidence in Revenue Durability, Not Forecast Speed Alone. NeuraCap AI — Immunology and Inflammation Therapeutics Coverage September 2026 · Prepared by NeuraCap AI · Confidential Immunology and Inflammation Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20
Sources and methodology
This report covers Immunology and Inflammation Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Immunology and Inflammation Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 16 listed companies whose core business is Immunology and Inflammation Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbbVie Inc. (ABBV), Abivax S.A. (ABVX), Alumis Inc. (ALMS), Alvotech (ALVO), argenx SE (ARGX), Arcutis Biotherapeutics, Inc. (ARQT), aTyr Pharma, Inc. (ATYR), Coya Therapeutics, Inc. (COYA), DBV Technologies S.A. (DBVT), ImageneBio Inc (IMA), Immunic, Inc. (IMUX), Kiniksa Pharmaceuticals International, plc (KNSA), Palisade Bio, Inc. (PALI), ARS Pharmaceuticals, Inc. (SPRY), Spyre Therapeutics, Inc. (SYRE), Vera Therapeutics, Inc. (VERA). The market map groups them by business vertical — Clinical-stage immunology and inflammation developers: 13 companies (ARGX, ABVX, SYRE, ARQT, VERA, DBVT, ALMS, SPRY, PALI, COYA, ATYR, IMA, IMUX); Adjacent models: 3 companies (ABBV, KNSA, ALVO). 7 of the 16 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Immunology and Inflammation Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Immunology and Inflammation Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 16 listed companies whose core business is Immunology and Inflammation Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: AbbVie Inc. (ABBV), Abivax S.A. (ABVX), Alumis Inc. (ALMS), Alvotech (ALVO), argenx SE (ARGX), Arcutis Biotherapeutics, Inc. (ARQT), aTyr Pharma, Inc. (ATYR), Coya Therapeutics, Inc. (COYA), DBV Technologies S.A. (DBVT), ImageneBio Inc (IMA), Immunic, Inc. (IMUX), Kiniksa Pharmaceuticals International, plc (KNSA), Palisade Bio, Inc. (PALI), ARS Pharmaceuticals, Inc. (SPRY), Spyre Therapeutics, Inc. (SYRE), Vera Therapeutics, Inc. (VERA). The market map groups them by business vertical — Clinical-stage immunology and inflammation developers: 13 companies (ARGX, ABVX, SYRE, ARQT, VERA, DBVT, ALMS, SPRY, PALI, COYA, ATYR, IMA, IMUX); Adjacent models: 3 companies (ABBV, KNSA, ALVO). 7 of the 16 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
66 records failed a validation gate and never feed a statistic in this report (56 excluded from aggregate; 10 quarantined). Each exclusion, with its reason: ABVX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABVX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABVX — Implied EBITDA margin -6647.4% outside the plausible band [-100%, 80%] (effect: quarantined) · ABVX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ABVX — Implied EBITDA margin -230.0% outside the plausible band [-100%, 80%] (effect: quarantined) · ABVX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ALMS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ALMS — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ALMS — Implied EBITDA margin -1285.9% outside the plausible band [-100%, 80%] (effect: quarantined) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALMS — Revenue for CY2026E is 0.27x the CY2025A value and 4.2x smaller than CY2027E; the value is on a different basis from the periods either side of it and cannot be compared with them (effect: quarantined) · ALVO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALVO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARQT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARQT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ATYR — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ATYR — Implied EBITDA margin -40038.9% outside the plausible band [-100%, 80%] (effect: quarantined) · ATYR — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ATYR — Implied EBITDA margin -1852.1% outside the plausible band [-100%, 80%] (effect: quarantined) · ATYR — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ATYR — Implied EBITDA margin -941.1% outside the plausible band [-100%, 80%] (effect: quarantined) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: EV / Revenue on CY2026E consensus (7 of 16 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2026E is the lead convention: it is the sector-appropriate prior for Immunology and Inflammation Therapeutics and it clears the coverage gate with 13 of 16 companies (81%). EV / EBITDA, P / E are carried as a cross-check. A revenue lens is used rather than a profit multiple because the cohort's median forward revenue growth is 27%, and a set priced on growth is read on revenue. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 4 of 16 companies; EV / rEVenue: 13 of 16 companies; P/E: 3 of 16 companies. Forward coverage was insufficient on the preferred basis; the cohort is presented on CY2026E. 2 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 10 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥10.2x, Core 5.9x–10.2x, Discount <5.9x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 7.9x = median(ev_revenue CY2026E) (7 rated companies) · 42.2x = median(ev_revenue CY2026E) within Premium tier (n=2) · 7.9x = median(ev_revenue CY2026E) within Core tier (n=3) · 4.0x = median(ev_revenue CY2026E) within Discount tier (n=2) · 6.2x = median(ev_revenue CY2026E) | growth ≥ 23% (n=3) · 7.9x = median(ev_revenue CY2026E) | growth < 23% (n=3) · 56% = median Rule of 40 score (revenue growth + EBITDA margin) (n=4)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Immunology and Inflammation Therapeutics recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 12 transactions were recorded for this industry; 7 are shown. 5 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 10 × deal value unit unresolved; 8 × no evidence record; 1 × duplicate precedent id. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 344 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- argenx SE (ARGX) (sec.gov)
- Abivax S.A. (ABVX) (sec.gov)
- Arcutis (ARQT) (sec.gov)
- Vera Therapeutics (VERA) (sec.gov)
- DBV Technologies (DBVT) (sec.gov)
- Alumis (ALMS) (sec.gov)
- ARS (SPRY) (sec.gov)
- Palisade Bio (PALI) (sec.gov)
- AbbVie (ABBV) (sec.gov)
- Kiniksa (KNSA) (sec.gov)
- $2.9B (sec.gov)
- 4.9x (sec.gov)
- $659M (sec.gov)
- $470M (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- $6.6B (sec.gov)
- n/a (sec.gov)
- sec.gov (339) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- M&A Update · 29 September 2026Life Sciences Research Reagents and Supplies M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Life Sciences Research Reagents and Supplies Sector Outlook — September 2026
- M&A Update · 29 September 2026Life Sciences Tools and Instruments M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Life Sciences Tools and Instruments Sector Outlook — September 2026
Want this analysis for a company in Immunology and Inflammation Therapeutics?
Company valuation reports run the same method against a single business — public or private.
